GeNeuro SA announces the postponement of the publication of the Company’s 2024 annual results
Geneva, Switzerland, 12 May 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of the publication of its December 31, 2024 annual results and annual financial report in order to be able to take into account the financial […]
GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
Geneva, Switzerland, 28 January 2025 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has renewed the provisional debt-restructuring moratorium granted to the Company in September 2024. The moratorium has been extended for an […]
Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications
Geneva, Switzerland, December 11th, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, Long-COVID or post-COVID), today announced that, as planned in […]